Research Studies at the Lugene Eye Institute
Acucela
- An investigator-masked, dose-escalation study to determine the safety,
tolerability, pharmacokinetics, and efficacy of XXX ophthalmic solution
in subjects with primary open angle glaucoma or ocular hypertension (2011)
- A Phase 3 Study to determine the efficacy, and safety of XXX in subjects
with Dry Eye Syndrome (2012)
Allergan
- A 6-day, phase 3, multicenter, randomized, double-masked, parallel study
to compare the safety and efficacy of XXX 0.5 ophthalmic solution with
that of vehicle in the treatment of acute bacterial conjunctivitis (2007)
- A multicenter, randomized, double-masked, parallel-group study to evaluate
the safety and efficacy of XXX ophthalmic emulsion 0.05% (XXX) administered
4 times daily for 16 weeks in patients with primary pterygium (2007)
- Ophthalmic AGN-195263 for the treatment of meibomian gland dysfunction (2012)
- Evaluation of bimatoprost 0.01% and bimatoprost 0.03% in patients with
glaucoma or ocular hypertension (2013)
Alcon
- An evaluation of the safety and efficacy of XXX ophthalmic solution 0.5%
for treatment of bacterial conjunctivitis in the USA (2008)
- A randomized double-masked study of XXX XX 0.25% (XXX) versus vehicle in
dry eye patients (2009)
- An evaluation of the efficacy and safety of XXX ophthalmic solution for
the treatment of adenoviral conjunctivitis (2009)
- A randomized, double-masked study of XXX 0.05% ophthalmic solution and
XXX 0.10% ophthalmic solution versus XXX vehicle in the treatment of dry
eye (2009)
Altheos
- A phase 1/2a randomized, investigator-masked, placebo and active-controlled,
dose-ranging study of the safety and efficacy of XXX in subjects with
primary open angle glaucoma (POAG) and ocular hypertension (2012)
Bausch & Lomb
- A randomized, multicenter, double-masked, parallel-group clinical safety
and efficacy evaluation of XXX etabonate ophthalmic gel, 0.5% versus vehicle
for the treatment of inflammation and pain following cataract surgery (2008)
- A clinical safety and efficacy evaluation of XXX (XXX 0.5% and XXX 0.3%
ophthalmic suspension) compared to XXX (XXX ophthalmic suspension 0.5%),
XXX ophthalmic solution USP, 0.3%, and the vehicle of XXX for the treatment
of blepharoconjunctivitis in pediatric subjects (2008)
- A randomized, double-masked, parallel-group, vehicle-controlled, multicenter,
exploratory study assessing safety and efficacy of XXX ophthalmic suspension
in dry eye syndrome (2010)
- A randomized, double-masked, parallel-group, dose-finding Study Comparing
- the Safety and Efficacy of xxx (0.006%, 0.012%, 0.024% and 0.040%) to XXX
0.005% in subjects with open angle glaucoma or ocular hypertension (2010)
- A study to evaluate the safety of XXX (XXX ophthalmic suspension) 0.6%
compared to vehicle following TID dosing for 7 Days (2010)
- A randomized, double-masked, active-controlled, parallel-group, multicenter
study to evaluate the safety and efficacy of topical (XXX) ophthalmic
suspension compared with gatifloxacin 0.3% ophthalmic solution for the
treatment of presumed bacterial conjunctivitis in subjects from birth
to 31 days of age (2012)
- A randomized, multicenter, double-masked, parallelgroup study comparing
the safety and efficacy of (study drug) ophthalmic solution with timolol
maleate ophthalmic solution 0.5% in subjects with open-angle glaucoma
or ocular hypertension (2013)
Bayer
- Prospective case crossover study to assess whether XXX exposure in men
with erectile dysfunction increases the risk for the development of non-arthritic
anterior ischemic optic meuropathy (NAION) (2009)
Innopharma, Inc.
- A multi-center, double-masked, randomized, parallel assignment study to
determine the therapeutic equivalence of XXX 1% ophthalmic suspension
manufactured by Innopharma, Inc. with respect to Azopt ™ in patients
with primary open-angle glaucoma or ocular hypertension
Inotek
- A Phase I/II multi-center, randomized, double-masked, placebo-controlled,
dose-escalation study to evaluate the tolerability, safety, pharmacokinetics,
and pharmacodynamics (efficacy) of chronic twice-daily topical monocular
application of XXX ophthalmic formulation in adults with ocular hypertension
or primary open-angle glaucoma (2010)
Insite Vision
- A randomized, double-masked, parallel-group, comparative study to evaluate
the clinical efficacy and safety of XXX (1.0% XXX and 0.1% XXX) compared
to XXX alone, XXX 0.1% alone, and vehicle in the treatment of subjects
with nonbacterial blepharitis (2011)
ISTA
- Efficacy and safety of XXX ophthalmic solution QD vs. placebo QD for treatment
of ocular inflammation and pain associated with cataract surgery (2009)
- A dose-ranging study to evaluate the safety and efficacy of XXX ophthalmic
solution versus placebo in alleviating the signs and symptoms of dry eye
disease (2010)
Novabay
- A multicenter, randomized study of the efficacy and safety of (XXX) ophthalmic
solution for the treatment of adenoviral conjunctivitis (2012)
- A multicenter, randomized study of the efficacy and safety of (study drug)
ophthalmic solution 0.3% for the treatment of bacterial conjunctivitis (2013)
Novagali
- A multicenter, randomized, double-masked, 3 parallel arms placebo-controlled
study to assess the efficacy and safety of (study drug) emulsion administered
in pediatric patients with active severe vernal keratoconjunctivitis with
severe keratitis (2013)
SunPharma
- Comparison of the efficacy and safety of XXX, XXX 0.005% ophthalmic solution
(test) and XXX (XXX0.005% ophthalmic solution-reference) when administered
once daily in subjects with open angle glaucoma or ocular hypertension:
A Clinical Equivalence Study (2010)
- A clinical evaluation of safety of XXX's XXX 0.005% ophthalmic solution
when administered once daily in subjects with open angle Glaucoma or ocular
hypertension: An Open Label Extension Study (2010)
If you are interested in participating in a clinical trial, please
click here to inquire about any of our current open studies. You can also contact
our research department at (818) 246-2560.